Abstract
BackgroundHepatocellular carcinoma (HCC), is the fifth most common cancer in the world and the second most common cause of cancer-related deaths. Over 500,000 new HCC cases are diagnosed each year. Combining advanced genomic analysis with proteomic characterization not only has great potential in the discovery of useful biomarkers but also drives the development of new diagnostic methods.MethodsThis study obtained proteomic data from Clinical Proteomic Tumor Analysis Consortium (CPTAC) and validated in The Cancer Proteome Atlas (TCPA) and TCGA dataset to identify HCC biomarkers and the dysfunctional of proteogenomics.ResultsThe CPTAC database contained data for 159 patients diagnosed with Hepatitis-B related HCC and 422 differentially expressed proteins (112 upregulated and 310 downregulated proteins). Restricting our analysis to the intersection in survival-related proteins between CPTAC and TCPA database revealed four coverage survival-related proteins including PCNA, MSH6, CDK1, and ASNS.ConclusionThis study established a novel protein signature for HCC prognosis prediction using data retrieved from online databases. However, the signatures need to be verified using independent cohorts and functional experiments.
Highlights
Hepatocellular carcinoma (HCC), is the fifth most common cancer in the world and the second most common cause of cancer-related deaths
Proteomics data was downloaded from The Cancer Proteome Atlas (TCPA) and combined with clinical data from the cancer genomic maps (TCGA), and comprehensive analysis of proteomics performed through Clinical Proteomic Tumor Analysis Consortium (CPTAC)
gene ontology (GO) analysis revealed that the GO terms related to biological processes (BP) of differentially expressed proteins were enriched in fatty acid biosynthesis and catabolism, molecular function (MF) were mainly enriched in cofactor binding, coenzyme binding, vitamin binding, monooxygenase activity, carboxylic acid-binding, iron ion binding, and organic acid binding and cell component (CC) were mainly enriched in the mitochondrial matrix, MCM complex, collagen trimer, peroxisome, microbody, microbody part, peroxisomal part, peroxisomal matrix, and microbody lumen
Summary
Combining advanced genomic analysis with proteomic characterization has great potential in the discovery of useful biomarkers and drives the development of new diagnostic methods. Hepatocellular carcinoma (HCC), is the fifth most common cancer in the world and the second most common cause of cancer-related deaths. Over 500,000 new HCC cases are diagnosed each year [1]. Viral hepatitis and nonalcoholic steatohepatitis are the most common causes of cirrhosis which underlies approximately 80% of cases of HCC [2]. Despite the rapid advancements in medical technology, there are still no Proteomics is a field of research that studies the proteins at a large-scale level. Biomarker analysis uses highthroughput sequencing technologies in proteomics and
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
